Not Signed In - MAP Pharmaceuticals Reports Positive Phase 2 Results For Its Inhaled Migraine Drug Candidate
Fri, 02 Mar 2007 08:00 AM EST
... MAP Pharmaceuticals, Inc. announced today that its Tempo(TM) Migraine drug candidate met its primary endpoints in a Phase 2 clinical program consisting of two separate trials. The candidate is a proprietary orally inhaled formulation of dihydroergotamine (DHE) for the treatment of acute migraine. [click link for full article] ...
Related Topics
- Migraine
- Drug Safety
- Prescription Drugs
- Urinalysis
- Headache
- Steroids, Inhaled
- Drug Side Effects
- Drug Abuse
- Drug Information
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Reflexology
- Tb
- Phenylephrine Eye Solution
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Clinical Trials
- Well Baby Reports
- Tuberculosis Surveillance Reports
email this page
print this page
bookmark this page
feedback on this page
